Aurobindo Pharma USA, Inc. (Aurobindo) is a generic solid dosage, small molecule manufacturer, a wholly owned subsidiary of Aurobindo Pharma Limited. Aurobindo received their first pharmaceutical approval from the United States Food and Drug Administration in 2004. Although not among the original U.S. generic manufacturers, Aurobindo is one of the fastest growing pharmaceutical companies, and by 2015 became one of the top ten amongst all U. S. generic pharmaceutical companies for total scripts dispensed [Source: IMS National Prescription Audit].
Aurobindo boasts an expanded portfolio of 155 product families with approximately 400 individual product packages from a multitude of therapeutic categories.
Aurobindo operates three US facilities comprising over 300,000 sq. ft. of laboratory, manufacturing, packaging, warehousing, distribution, and administrative offices with more than 425 talented associates.
Team of Dedicated Professionals
The commercial operation is made up of dedicated professionals in the areas of sales, contract management, supply chain, warehousing, and distribution. With the anticipated expansion of 565,000 square feet from the recent purchase of 90 acres of land in central New Jersey, Aurobindo remains one of the most attractive companies with whom to conduct business. Whether it is the large pharmacy chain/wholesaler who requires extraordinary amounts of product or the mid-size entrepreneur who requires professional inventory management, Aurobindo works closely with its customers to exceed expectations.